Tag: 100-200

On October 20, 2011, Bretschneider, Thomas; Koehler, Adeline; Fischer, Reiner; Fuesslein, Martin; Jescke, Peter; Kluth, Joachim; Muehlthau, Friedrich August; Voerste, Arnd; Malsam, Olga; Goergens, Ulrich; Sato, Yoshitaka published a patent.Recommanded Product: 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid The title of the patent was Preparation of novel heterocyclic compounds as pest control agents. And the patent contained the following:

The invention relates to amides and thioamides of formula I, to a method for the producing same, and to the use thereof for treating animal pests. Compounds of formula I wherein A1 and A2 are independently H, halo, CN, NO2, alkyl, cycloalkyl and alkoxy; G1 is N and CA1; G2 is substituted thiazolyl, thiadiazolyl, and pyrazolyl; are claimed. Example compound II was prepared by reduction of 3-(4-methyl-5-nitrothiazol)pyridine; the resulting 4-methyl-2-(pyridin-3-yl)thiazol-5-amine underwent acylation with 3,3,3-trifluoropropanoyl chloride to give compound II. All the invention compounds were evaluated for their pesticidal activity (data given). The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).Recommanded Product: 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid

The Article related to heterocycle preparation pesticide, Heterocyclic Compounds (More Than One Hetero Atom): Thiazoles, Isothiazoles and other aspects.Recommanded Product: 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On July 27, 2006, Venkatesan, Aranapakam M.; Agarwal, Atul; Abe, Takao; Ushirogochi, Hideki; Yamamura, Itsuka; Ado, Mihira; Tsuyoshi, Takasaki; Dos Santos, Osvaldo; Gu, Yansong; Sum, Fuk-Wah; Li, Zhong; Francisco, Gerry; Lin, Yang-I.; Petersen, Peter J.; Yang, Youjun; Kumagai, Toshio; Weiss, William J.; Shlaes, David M.; Knox, James R.; Mansour, Tarek S. published an article.COA of Formula: C9H12N2O3 The title of the article was Structure-Activity Relationship of 6-Methylidene Penems Bearing 6,5 Bicyclic Heterocycles as Broad-Spectrum β-Lactamase Inhibitors: Evidence for 1,4-Thiazepine Intermediates with C7 R Stereochemistry by Computational Methods. And the article contained the following:

The design and synthesis of a series of 6-methylidene penems containing [6,5]-fused bicycles (thiophene, imidazole, or pyrazle-fused system) as novel class A, B, and C β-lactamase inhibitors is described. These penems proved to be potent inhibitors of the TEM-1 (class A) and AmpC (class C) β-lactamases and less so against the class B metallo-β-lactamase CcrA. Their in vitro and in vivo activities in combination with piperacillin are discussed. On the basis of the crystallog. structures of a serine-bound reaction intermediate of imidazo[2,1-c]oxazine I with SHV-1 (class A) and GC1 (class C) enzymes, compounds II (R = Q, Q1, Q2, etc.) were designed and synthesized. Penems are proposed to form a seven-membered 1,4 thiazepine ring in both class A and C β-lactamases. The interaction energy calculation for the enzyme-bound intermediates favor the formation of the C7 R enantiomer over the S enantiomer of the 1,4-thiazepine in both β-lactamases, which is consistent with those obtained from the crystal structure of I with SHV-1 and GC1. The experimental process involved the reaction of Ethyl 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate(cas: 153597-59-2).COA of Formula: C9H12N2O3

The Article related to methylidene penem preparation beta lactamase inhibitor structure activity, bactericide methylidene penem structure activity, Biomolecules and Their Synthetic Analogs: Beta-Lactam Fungal Metabolites and other aspects.COA of Formula: C9H12N2O3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 10, 2016, Bergman, Ylva Elisabet; Lessene, Romina; Ganame, Danny; Foitzik, Richard Charles; Morrow, Benjamin Joseph; Camerino, Michelle Ang; Walker, Scott Raymond; Lagiakos, H. Rachel; Feutrill, John; Stupple, Paul Anthony published a patent.Application of 1014631-89-0 The title of the patent was Preparation of aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5 inhibitors. And the patent contained the following:

The invention relates to compounds of formula I, II and III as PRMT5-inhibitors; their preparation and use in the treatment of cancer and hemoglobinopathy. Compounds of formula I, II and III wherein n = 1 and 2; R is H and Me; R1 is halo and Me; R2a and R2b are independently F, H, Me and CH2OH; R2c and R2n are independently F, H, Me and CH2OH; R3a and R3b are independently H and Me; R4a is OH, NH2, CONH2 and CH2OH; R4b is H and Me; R5 is H and Me; A is (un)substituted Ph, (un)substituted naphthyl; and (un)substituted C5-12 heteroaryl, are claimed. Example compound IV was prepared by acylation of 1-amino-3-((2,3-dihydro-1H-inden-2-yl)amino)propan-2-ol with 4-chlorobenzoic acid. The invention compounds were evaluated for their PRMT5 inhibitory activity. From the assay, it was determined that example IV exhibited IC50 value of 0.792 μM. The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).Application of 1014631-89-0

The Article related to aminoindane aminotetrahydronaphthalene aminobenzocyclobutane preparation prmt5 inhibitor treatment cancer hemoglobinopathy, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.Application of 1014631-89-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On March 10, 2016, Bergman, Ylva Elisabet; Foitzik, Richard Charles; Morrow, Benjamin Joseph; Camerino, Michelle Ang; Walker, Scott Raymond; Lagiakos, H. Rachel; Feutrill, John; Stevenson, Graeme Irvine; Stupple, Paul Anthony published a patent.SDS of cas: 1014631-89-0 The title of the patent was Preparation of tetrahydroisoquinoline derivatives as PRMT5 inhibitors. And the patent contained the following:

The invention relates to tetrahydroisoquinoline derivatives of formula I as PRMT5-inhibitors; their preparation and use in the treatment of cancer and hemoglobinopathy. Compounds of formula I, wherein n = 1 and 2; p is 0 and 1; R1 is halo and Me; R2a and R2b are independently F, H, Me and CH2OH; R2c and R2n are independently F, H, Me and CH2OH; R3a and R3b are independently H and Me; R4 is H and Me; R5 is H and Me; R6a and R6b are independently H and Me; A is (un)substituted Ph, (un)substituted naphthyl; and (un)substituted C5-12 heteroaryl, are claimed. Example compound II was prepared by amidation of 2-fluoro-4-(morpholine-4-carbonyl)benzoic acid with tert-Bu (S)-3-((R)-2-amino-1-hydroxyethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate followed by BOC-deprotection. The invention compounds were evaluated for their PRMT5 inhibitory activity. From the assay, it was determined that example II exhibited IC50 value of 0.383 μM. The experimental process involved the reaction of 1-(Pyridin-3-yl)-1H-pyrazole-4-carboxylic acid(cas: 1014631-89-0).SDS of cas: 1014631-89-0

The Article related to tetrahydroisoquinoline preparation prmt5 inhibitor treatment cancer hemoglobinopathy, Heterocyclic Compounds (One Hetero Atom): Quinolines and Isoquinolines and other aspects.SDS of cas: 1014631-89-0

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On November 18, 2021, Vu, Binh; Dominique, Romyr; Li, Hongju; Fahr, Bruce; Good, Andrew published a patent.Recommanded Product: 1340372-11-3 The title of the patent was Preparation of heteroaryl-substituted indole derivatives for restoring mutant p53 function. And the patent contained the following:

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The disclosure provided compounds of formula I capable of binding to mutant p53 and restoring the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Compounds of formula I [wherein X1 to X4 independently = N, O, S, (un)substituted C, etc.; X5 = CH, N, or (un)substituted NH; wherein at least one of X1 to X4 is a carbon atom connected to Q1; A = (un)substituted ring; Q1 = C=O, C=S, alkylene, etc.; m = 1, 2, 3, or 4; Y = N, O, or absent; R1 = alkyl, halo, (hetero)aryl, etc.; R2 = alkyl, alkenyl, aryl, etc.; R3 and R4 independently = alkyl, aryl, heteroaryl, etc.; R3 and R4 together with the nitrogen atom to which R3 and R4 are bound form a ring] and pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compound II was prepared a multistep procedure (preparation given). Exemplified I were evaluated for DNA binding activity using recombinant His-tag Y220C p53 DBD protein and TR-FRET anal. with some invention candidates demonstrating SC150 results in the range of 0μM to less than 2μM. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation. The experimental process involved the reaction of 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxylic acid(cas: 1340372-11-3).Recommanded Product: 1340372-11-3

The Article related to heteroaryl indole preparation mutant p53 restoration cancer progression, dna binding oncogene p53 stabilization heteroaryl indole, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 1340372-11-3

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 10, 2020, Cregg, James Joseph; Buckl, Andreas; Aay, Naing; Tambo-Ong, Arlyn A.; Koltun, Elena S.; Gill, Adrian Liam; Thompson, Severin; Gliedt, Micah J. published a patent.Reference of 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxylic acid The title of the patent was Preparation of bicyclic heterocyclyl compounds as SOS1 modulators. And the patent contained the following:

The present disclosure is directed to the title compounds I [Q1 = CH or N; Q4 = CH, C, or N; each Q2 = (independently) CR1 or N (wherein one Q2 = N and the other Q2 = CR1); each Q3 and Q5 = (independently) (un)substituted CH2, NH, CO, O, S, or SO2; wherein at least one of Q1-Q5 = N, (un)substituted NH, O, or SO2; m = 0-3; n = 0-3; wherein when m = 0, then n is not 0; R1 = H, alkyl, halo, etc.; L2 = a bond, C(O), C(O)O, etc.; R2 = H, alkyl, cycloalkyl, etc.; R3 and R4 = (independently) H or alkyl optionally substituted with halo or OH; wherein at least one of R3 and R4 = H or wherein R3 and R4 together with the atom to which they are attached combine to form a 3-6 membered cycloalkyl; A = (un)substituted 6-membered aryl or 5-6 membered heteroaryl; with the proviso] or pharmaceutically acceptable salts, solvates, isomers, prodrugs, or tautomers thereof, that are modulators of SOS1 and their use in the treatment of disease. E.g., a multi-step synthesis of (1R)-II, starting from 2,4-dichloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine and morpholine-4-carbonyl chloride, was described. Exemplified compounds I were evaluated for their activity as SOS1 modulators (data given for representative compounds I). Also disclosed are pharmaceutical compositions comprising compounds I. The experimental process involved the reaction of 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxylic acid(cas: 1340372-11-3).Reference of 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxylic acid

The Article related to bicyclic heterocyclyl compound pyrrolopyrimidinamine cyclopentapyrimidinamine pyrimidoazepinamine preparation sos1 modulator, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-4-carboxylic acid

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On September 24, 2021, Zhao, Zhiming; Liu, Lifeng; Liu, Qingyun; Wang, Hailong; Guan, Huiping; Da, Chenxiao; Chen, Xi; Xu, Guiliang published a patent.Safety of Ethyl 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate The title of the patent was Polyheterocyclic substituted pyrimidine or pyridylamine derivatives, compositions thereof and medical applications thereof. And the patent contained the following:

The invention discloses the polyheterocyclic substituted pyrimidine or pyridylamine derivatives (e.g., I) as adenosine receptor antagonists, which have significant adenosine A2A receptor and/or adenosine A2B receptor antagonistic activities. For example, 3-(2-amino-6-(1-((5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl)methyl)-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl)-2-methylbenzonitrile (I) was prepared via reaction of 3-bromo-2-methylbenzonitrile with bis(pinacolato)diboron, followed by Suzuki coupling reaction with 2-amino-4,6-dichloropyrimidine, followed by Sonogashira coupling with (triisopropylsilyl)acetylene, followed by Click reaction with 2-(azidomethyl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole. The title compounds can be used in medicines for treating diseases mediated by adenosine A2A receptor and/or adenosine A2B receptor. The experimental process involved the reaction of Ethyl 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate(cas: 153597-59-2).Safety of Ethyl 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate

The Article related to pyrimidine pyridylamine triazole adenosine receptor antagonist immunomodulator antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of Ethyl 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxylate

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On August 18, 2016, Gray, Nathanael S.; Hatcher, John; Choi, Hwan Geun published a patent.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was LRRK2 inhibitors and methods of making and using the same. And the patent contained the following:

The invention relates to compounds of formula I, II, and III as LRRK2 inhibitors; their preparation and use in the treatment of neurodegenerative diseases, such as Parkinson’s disease. Compounds of formula I wherein Rx is NRARB, substituted piperidinylmethanone, substituted morpholinomethanone, etc.; RA and RB are independently (un)substituted C1-6 alkyl and COR7; R7 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl; X1, X2 and X3 are independently N, NH and derivatives, substituted C; Rn is H and (un)substituted C1-6 alkyl; each R1 is independently (un)substituted C1-6 alkyl, (un)substituted C1-6 alkoxy and halo; m = 0 – 3; R2 is H, alkoxy, halo, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound IV was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their LRRK2 inhibitory activity (some data given). The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrrolopyrimidine preparation lrrk2 inhibitor treatment neurodegenerative disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Name: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On June 25, 2020, Brenneman, Jehrod Burnett; Krall, Elsa Beyer; Schlabach, Michael; Wylie, Andrew Alistair published a patent.Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine The title of the patent was Preparation of substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors. And the patent contained the following:

The present disclosure provides compounds having formula I and the pharmaceutically acceptable salts and solvates thereof, wherein X1, X2 is independently N and CR2; R1 and R2 are independently H, halo, cyano, (un)substituted alkyl, etc.; R3 is (un)substituted Ph, pyridinyl, pyrazolyl, etc.; X11 and X12 is independently N and CH; R5′ is H, (un)substituted C1-6alkyl, (un)substituted C1-6alkoxy, etc.; R5 is (un)substituted C1-6alkyl, (un)substituted C2-6alkenyl, C1-6haloalkyl, etc.; R6 and R7 is independently H, halo, CN, (un)substituted alkenyl, etc. The present disclosure is also directed to the use of compounds of Formula I to inhibit a USP1 protein and to treat a disorder responsive to the inhibition of USP1 proteins and USP1 activity. Example compound II was prepared via a multistep procedure (procedure given). From the assay, it was determined that example compound II exhibited IC50 value of > 200 nM towards USP1. The experimental process involved the reaction of 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine(cas: 98138-75-1).Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

The Article related to pyrazolopyrimidines purine preparation usp1 inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 6-Chloro-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

On February 1, 2007, Oslob, Johan D.; Yu, Chul Hyun published a patent.Reference of 1-Methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ol The title of the patent was Pyrazolopyrimidines useful as Aurora kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of Aurora kinase mediated diseases. And the patent contained the following:

The invention provides compounds having the formula I, which are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases. Compounds of formula I wherein dotted line is double bond as valency permits; R2 is H, halo, CN, NO2, (hetero)aliphatic, (hetero)alicyclic and (hetero)aromatic moiety; R4 is absent, H, (hetero)aliphatic, (hetero)alicyclic, and (hetero)aromatic moiety; if R4 is absent, X1 and X2 are independently NH and derivatives and CR1 proviso that only one of X1 and X2 are CR1; if R4 is present X1 and X2 are independently N and derivatives, and CR1, proviso that only one of X1 and X2 is CR1; R1 is H, halo, CN, No2, (hetero)aliphatic, etc.; L1 is 2-8 atom heteroaliph. linker; L2 is 1-6 atom heteroaliph. linker; Y is (hetero)alicyclic, and (hetero)aromatic moiety; Z is (hetero)alicyclic, (hetero)aliphatic, and (hetero)aromatic moiety; are claimed. Example compound II was prepared by amination of 4-chloro-5-methylpyrazolopyrimidine derivative with 2-[2-(3-trifluoromethylphenylurido)thiazol-2-yl]ethylamine. All the invention compounds were evaluated for their Aurora kinase inhibitory activity. The experimental process involved the reaction of 1-Methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ol(cas: 314021-93-7).Reference of 1-Methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ol

The Article related to pyrazolo pyrimidine preparation aurora kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Reference of 1-Methyl-1H-pyrazolo[4,3-d]pyrimidin-7-ol

Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics